论文部分内容阅读
目的探讨巨大肝癌的综合治疗的方法和疗效。方法回顾性分析近8年本院收治的160例原发性巨大肝癌的手术及非手术治疗情况。112例行手术治疗,其中12例行经皮股动脉穿刺肝动脉化疗(TACE)后行Ⅱ期手术切除治疗,6例无法切除行肝动脉栓塞(HAI)、肝动脉结扎(HAL),32例单纯行手术治疗,62例手术治疗后行周围静脉或腹腔内化疗;30例行介入治疗TACE;18例行周围静脉或腹腔内化疗。结果手术并发症发生率10.7%,术后1个月内死亡率0.98%,术后单纯手术组1、2、3年的生存率分别为78.1%,62.5%,46.5%,手术加周围静脉或腹腔内化疗组1、2、3年的生存率分别为87.8%,75.6%,60.8%。结论巨大肝癌应以手术为首选方法,结合HAI、HAL、TACE化疗及免疫、激素和中医中药治疗能提高患者的远期生存。
Objective To explore the comprehensive treatment of giant hepatocellular carcinoma and its efficacy. Methods Retrospective analysis of surgical and non-surgical treatment of 160 cases of primary hepatocellular carcinoma admitted to our hospital in recent 8 years. One hundred and twelve patients underwent surgical resection. Twenty-two patients underwent percutaneous transhepatic arterial chemotherapy (TACE) underwent surgical resection. Six patients were unresectable with hepatic artery embolization (HAI), hepatic artery ligation (HAL), and 32 Surgical treatment alone, 62 cases of surgical treatment after peripheral vein or intraperitoneal chemotherapy; 30 cases of interventional TACE; 18 cases of peripheral vein or intraperitoneal chemotherapy. Results The incidence of complications was 10.7% and the mortality rate within 1 month after operation was 0.98%. The survival rates at 1, 2 and 3 years after operation in the simple operation group were 78.1%, 62.5% and 46.5% respectively. Surgical operations including peripheral vein or The survival rates at 1, 2 and 3 years after intraperitoneal chemotherapy were 87.8%, 75.6% and 60.8% respectively. Conclusion Large hepatocellular carcinoma should be surgically treated as the preferred method. Combined with HAI, HAL, TACE chemotherapy and immunotherapy, hormones and traditional Chinese medicine can improve the long-term survival of patients.